/CGTX
CGTX Stock - Cognition Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$1.54+2.67%
+$0.04 (+2.67%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.67
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.69
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CGTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.52 – $1.56
TARGET (TP)$1.77
STOP LOSS$1.42
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.24
52W High$3.83
52W Low$0.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | $-235,000 | N/A | $-98,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-53,966,000 | $-50,724,000 | $-43,551,000 | $-28,598,000 | $-17,407,000 |
| Net Income | $-33,971,000 | $-25,788,000 | $757,000 | $-11,716,000 | $-10,072,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.85 | $-0.86 | $-0.74 | $-0.73 | $-0.55 |
Company Overview
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
50%
Hold / Neutral
1
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
1 Bullish1 Neutral/Bearish
Price Targets
$2
Average Target
↓ 2.6% Downside
Now
$2
Low
$2
Average
$2
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 19th 2024 | B. Riley Securities | Upgrade | Buy | $1.5← $1 |
| July 30th 2024 | Cantor Fitzgerald | Downgrade | Neutral | - |
Earnings History & Surprises
CGTXBeat Rate
59%
Last 17 quarters
Avg Surprise
-324.1%
EPS vs Estimate
Beats / Misses
10/7
Last 12 quarters
Latest EPS
$-0.06
Q4 2025
EPS Surprise History
Q1 24
+28.9%
$-0.27vs$-0.38
Q2 24
-17.4%
$-0.27vs$-0.23
Q3 24
+18.2%
$-0.18vs$-0.22
Q4 24
-4.2%
$-0.25vs$-0.24
Q1 25
-6.3%
$-0.17vs$-0.16
Q2 25
-16.7%
$-0.14vs$-0.12
Q3 25
+8.3%
$-0.11vs$-0.12
Q4 25
+14.3%
$-0.06vs$-0.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.06 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.12 | $-0.11 | +8.3% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.12 | $-0.14 | -16.7% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.16 | $-0.17 | -6.3% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.24 | $-0.25 | -4.2% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.22 | $-0.18 | +18.2% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.23 | $-0.27 | -17.4% | ✗ MISS |
Q1 2024 | Mar 26, 2024 | $-0.38 | $-0.27 | +28.9% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.31 | $-0.22 | +29.0% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.25 | $-0.16 | +36.0% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.17 | $-0.21 | -23.5% | ✗ MISS |
Q1 2023 | Mar 23, 2023 | $-0.49 | $-0.20 | +59.2% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.55 | $-0.29 | +47.3% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.31 | $-0.25 | +19.4% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.27 | $-0.17 | +37.0% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | $-0.26 | $-11.74 | -4415.4% | ✗ MISS |
Q4 2021 | Nov 17, 2021 | $-0.57 | $-8.12 | -1324.6% | ✗ MISS |
Q4 2021 | Oct 8, 2021 | — | $-0.07 | — | — |
Latest News
Cognition Therapeutics Files Prospectus To Offer Up To $300M In Securities
➖ NeutralBenzinga•Dec 18, 2025, 09:08 PM
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target
📈 PositiveBenzinga•Dec 4, 2025, 11:15 AM
Cognition Therapeutics Reaches Full Patients Enrollment For Zervimesine In Dementia Trial
📈 PositiveBenzinga•Dec 3, 2025, 12:34 PM
Cognition Therapeutics Presented Plans For Registrational Program For Zervimesine In Mild-To-Moderate Alzheimer's Disease
📈 PositiveBenzinga•Dec 1, 2025, 12:40 PM
B. Riley Securities Reiterates Buy on Cognition Therapeutics, Raises Price Target to $3
📈 PositiveBenzinga•Nov 21, 2025, 04:10 PM
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target
📈 PositiveBenzinga•Nov 19, 2025, 11:55 AM•Also:
Cognition Therapeutics Reaches Target Enrollment Of 540 Patients In Phase 2 START Trial To Evaluate Zervimesine To Treat Early Alzheimer's Disease
📈 PositiveBenzinga•Nov 13, 2025, 12:38 PM
Cognition Therapeutics Q3 EPS $(0.06) Beats $(0.09) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:37 PM
Reported Earlier: Cognition Therapeutics Reports Zervimesine (CT1812) Results In Phase 2 SHIMMER DLB, SHINE Alzheimer's & MAGNIFY Dry AMD Studies; Moving Toward Phase 3 Trials
📈 PositiveBenzinga•Sep 15, 2025, 03:53 PM•Also:
Cognition Therapeutics 2 'START' Study Of In Early Alzheimer's Disease Reaches 75% Enrollment Target
📈 PositiveBenzinga•Sep 3, 2025, 11:31 AM
Cognition Therapeutics Closes $30M Registered Direct Offering Of 14.7M Shares At $2.05/Share
➖ NeutralBenzinga•Sep 2, 2025, 08:01 PM
Cognition Therapeutics shares are trading lower after the company announced a $30 million registered direct offering.
📉 NegativeBenzinga•Aug 28, 2025, 01:07 PM
Reported Earlier, Cognition Therapeutics Secures $30M From Registered Direct Offering Made To Two Fundamental Institutional Investors
📈 PositiveBenzinga•Aug 28, 2025, 06:39 AM
Cognition Therapeutics Regains Compliance With Nasdaq
📈 PositiveBenzinga•Aug 26, 2025, 08:01 PM
Cognition soars 35% after positive FDA meeting on Alzheimer's asset zervimesine
📈 PositiveSeeking Alpha•Jul 10, 2025, 07:29 PM•Also: ,
Frequently Asked Questions about CGTX
What is CGTX's current stock price?
Cognition Therapeutics, Inc. (CGTX) is currently trading at $1.54 per share. The stock has moved +2.67% today.
What is the analyst price target for CGTX?
No analyst price targets are currently available for this stock.
What sector is Cognition Therapeutics, Inc. in?
Cognition Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CGTX's market cap?
Cognition Therapeutics, Inc. has a market capitalization of $0.11 billion, making it a small-cap company.
Does CGTX pay dividends?
No, Cognition Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGEN
Agenus Inc.
$3.44
Mkt Cap: $0.1B
ATOS
Atossa Therapeutics, Inc.
$0.73
Mkt Cap: $0.1B
GLSI
Greenwich LifeSciences, Inc.
$13.01
Mkt Cap: $0.2B
IRD
Opus Genetics, Inc.
$2.00
Mkt Cap: $0.1B
MCRB
Seres Therapeutics, Inc.
$14.98
Mkt Cap: $0.1B
SEER
Seer, Inc.
$1.79
Mkt Cap: $0.1B
SPRO
Spero Therapeutics, Inc.
$2.32
Mkt Cap: $0.1B
SRZN
Surrozen, Inc.
$21.76
Mkt Cap: $0.2B
TVGN
Tevogen Bio Holdings Inc.
$0.38
Mkt Cap: $0.1B
VTGN
VistaGen Therapeutics, Inc.
$0.78
Mkt Cap: $0.0B
Explore stocks similar to CGTX for comparison